Merck & Company Inc (MRK)vsRani Therapeutics Holdings Inc (RANI)
MRK
Merck & Company Inc
$120.79
-2.77%
HEALTHCARE · Cap: $285.64B
RANI
Rani Therapeutics Holdings Inc
$0.88
+2.03%
HEALTHCARE · Cap: $107.58M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2075255% more annual revenue ($65.77B vs $3.17M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).
MRK
Hold50
out of 100
Grade: D+
RANI
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-49.3%
Fair Value
$80.88
Current Price
$120.79
$39.91 premium
Margin of Safety
+77.3%
Fair Value
$5.50
Current Price
$0.88
$4.62 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Revenue surging 893.0% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : RANI
The strongest argument for RANI centers on Revenue Growth, Debt/Equity. Revenue growth of 893.0% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : RANI
The primary concerns for RANI are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
MRK profiles as a value stock while RANI is a hypergrowth play — different risk/reward profiles.
RANI carries more volatility with a beta of 0.76 — expect wider price swings.
RANI is growing revenue faster at 893.0% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (50/100 vs 28/100). RANI offers better value entry with a 77.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Rani Therapeutics Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Rani Therapeutics Holdings Inc. is at the forefront of biotechnology innovation, transforming injectable therapies with its proprietary RaniPill™ technology that allows for oral delivery of biologics. This cutting-edge platform addresses significant patient adherence challenges, aiming to enhance treatment efficacy while meeting the rising demand for non-invasive therapeutic options. With a robust and diverse pipeline targeting multiple therapeutic areas, Rani Therapeutics is strategically positioned to disrupt traditional drug delivery paradigms. The company's commitment to research and development, coupled with strategic collaborations, underpins its potential for significant growth and impactful contributions to the pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?